Healthcare Industry News: Zevalin
News Release - March 14, 2018
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead ManufacturingFormer Amgen executive will oversee company’s pharmaceutical manufacturing operations
LOS ANGELES, March 14, 2018 -- (Healthcare Sales & Marketing Network) -- CURE Pharmaceutical, (OTC:CURR), an innovative drug delivery and development company, today named Steven Ruhl Vice President of Manufacturing. Bringing more than 35 years of experience, Ruhl will oversee all process development and manufacturing operations.
Ruhl’s expertise spans more than three decades in the areas of drug substance and drug products process development, production facility design, process equipment, construction and Current Good Manufacturing Process (CGMP) management. For the last 11 years, he’s held several leadership roles at the world's largest independent biotechnology firm, Amgen, focusing on product development and lifecycle management for the company’s commercial products.
“CURE is ahead of the game when it comes to product development and drug delivery,” said Ruhl. “This is the perfect time to help a leader in cutting-edge technology, make the transition to high volume commercial manufacturing and ultimately deliver a new patient experience with safer and more effective medications.”
Previously, Ruhl held management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals. While working at IDEC, he pioneered breakthroughs for monoclonal antibody therapies with Rituxan®. Ruhl co-led the chemistry, manufacturing and control (CMC) development for Zevalin® radioimmune conjugate. Ruhl has a Bachelor of Science degree in Microbiology and Immunology from Brigham Young University.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Source: CURE Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.